Tumor Clinical Trials

2,320 recruitingLast updated: June 17, 2026

There are 2,320 actively recruiting tumor clinical trials across 76 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Tumor Trials at a Glance

2,320 actively recruiting trials for tumor are listed on ClinicalTrialsFinder across 6 cities in 76 countries. The largest study group is Phase 1 with 1,202 trials, with the heaviest enrollment activity in Houston, New York, and Beijing. Lead sponsors running tumor studies include National Cancer Institute (NCI), Sichuan Baili Pharmaceutical Co., Ltd., and Memorial Sloan Kettering Cancer Center.

Treatments under study

About Tumor Clinical Trials

Looking for clinical trials for Tumor? There are currently 31 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 2,320 trials

Recruiting
Phase 2

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Neuroendocrine CarcinomaCarcinoma, NeuroendocrineTumor, Neuroendocrine+2 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06406465
Recruiting
Not Applicable

Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors

Malignant Tumor
Alpha Tau Medical LTD.100 enrolled1 locationNCT05781555
Recruiting
Phase 1Phase 2

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Brain CancerGBMGlioma+12 more
National Institute of Neurological Disorders and Stroke (NINDS)40 enrolled1 locationNCT07416188
Recruiting

Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol

Solid Tumor
Memorial Sloan Kettering Cancer Center3,692 enrolled1 locationNCT05390827
Recruiting

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Solid TumorOther Solid TumorsVery Rare Tumors+2 more
National Cancer Institute (NCI)4,000 enrolled1 locationNCT07489378
Recruiting

A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients

Pan-tumor(NSCLC, GYN Cancers, BTC and UC)
AstraZeneca2,100 enrolled14 locationsNCT07404202
Recruiting
Phase 2

Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)

Tenosynovial Giant Cell Tumor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany20 enrolled3 locationsNCT07499362
Recruiting
Phase 1Phase 2

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced/Metastatic Solid Tumors
Crescent Biopharma, Inc.290 enrolled17 locationsNCT07335497
Recruiting
Not Applicable

Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors

Skin CancerCutaneous TumorCutaneous Metastasis
Alpha Tau Medical LTD.80 enrolled2 locationsNCT04068155
Recruiting
Phase 1

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting

DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Pleuropulmonary BlastomaCystic NephromaNasal Chondromesenchymal Hamartoma+2 more
National Cancer Institute (NCI)1,500 enrolled2 locationsNCT01247597
Recruiting

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

SarcomaEndocrine TumorsNeuroblastoma+2 more
National Cancer Institute (NCI)6,035 enrolled5 locationsNCT01109394
Recruiting

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

Kidney CancerRenal Tumor HistologyCutaneous Leiomyoma
National Cancer Institute (NCI)1,130 enrolled1 locationNCT00050752
Recruiting

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

Familial CancerMesotheliomaBRCA1-Associated Protein-1 (BAP1) Mutations+1 more
National Cancer Institute (NCI)300 enrolled1 locationNCT04431024
Recruiting

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

Gastric CancerGastric NeoplasmGastrointestinal Stromal Tumor (GIST)+2 more
National Cancer Institute (NCI)400 enrolled1 locationNCT04557969
Recruiting

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Endocrine TumorsNeuroblastomaThyroid Neoplasms+2 more
National Cancer Institute (NCI)2,415 enrolled1 locationNCT01005654
Recruiting
Phase 2

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Squamous Cell Carcinoma of the BladderAdenocarcinoma of the BladderTesticular Germ Cell Tumors
National Cancer Institute (NCI)68 enrolled1 locationNCT06041503
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled578 locationsNCT03866382
Recruiting

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Solid TumorPediatric Solid TumorMalignant Solid Tumors+2 more
National Cancer Institute (NCI)10,000 enrolled3 locationsNCT03739827
Recruiting
Phase 1

Study of STP938 (Dencatistat) in Advanced Solid Tumours

Solid Tumor
Step Pharma, SAS70 enrolled7 locationsNCT06297525